Jean Jacques Bienaime - 21 Dec 2021 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
21 Dec 2021
Net transactions value
-$500,778
Form type
4
Filing time
14 Jan 2022, 19:45:51 UTC
Previous filing
17 Dec 2021
Next filing
10 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Small acquisition under Rule 16a-6 $8,922 +100 +0.03% $89.22 303,789 21 Dec 2021 Direct
transaction BMRN Common Stock Options Exercise $187,300 +5,000 +1.6% $37.46 308,789 12 Jan 2022 Direct F1
transaction BMRN Common Stock Sale $445,000 -5,000 -1.6% $89.00 303,789 12 Jan 2022 Direct F1, F2
transaction BMRN Common Stock Options Exercise $187,300 +5,000 +1.6% $37.46 308,789 13 Jan 2022 Direct F1
transaction BMRN Common Stock Sale $439,300 -5,000 -1.6% $87.86 303,789 13 Jan 2022 Direct F1
holding BMRN Common Stock 247,533 21 Dec 2021 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -5,000 -4% $0.000000 120,000 12 Jan 2022 Common Stock 5,000 $37.46 Direct F1, F3
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -5,000 -4.2% $0.000000 115,000 13 Jan 2022 Common Stock 5,000 $37.46 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on October 13, 2021.
F2 The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's purchase of shares at a price of $78.7700 on September 9, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.